Insights
Sort by:
Client Alerts 924 results
Client Alert | 3 min read | 07.13.26
Amici Rally Behind Liberty Global, Urging Tenth Circuit to Rein in Economic Substance Doctrine
Client Alert | 4 min read | 07.09.26
UCMR 6: EPA Sidesteps Microplastics, For Now
Client Alert | 2 min read | 07.08.26
When Sharing Becomes Collusion: Bipartisan AG Settlement Outlines Pricing Compliance
Client Alert | 6 min read | 07.07.26
Client Alert | 2 min read | 06.29.26
When Trade Secret Theft Becomes Racketeering: What the Fifth Circuit’s New Ruling Means
Client Alert | 2 min read | 06.15.26
Kansas Federal Court Applies “Selective Enforcement” Theory to Reject DTSA Claim
Client Alert | 4 min read | 06.12.26
Auto Dealers: The FTC Is Back in the Driver’s Seat — Warning Letters Signal Renewed Federal Scrutiny
Client Alert | 4 min read | 06.04.26
Surveillance Pricing Update: California’s Sweeping AB 2564 Passes Assembly and Heads to Senate
Client Alert | 5 min read | 05.19.26
Navigating International Arbitration Disputes Ahead of the 2026 FIFA World Cup
Client Alert | 7 min read | 05.18.26
Client Alert | 6 min read | 05.18.26
Seventh Circuit Opens the Door on Loyalty Program Tax Exclusions
Client Alert | 5 min read | 05.18.26
The Hidden Ingredient Problem: PFAS Litigation and Regulation Are Reshaping the Beauty Industry
Client Alert | 8 min read | 05.14.26
UK Collective Actions: Stricter Certification and What It Means for Funders
Client Alert | 3 min read | 05.06.26
Government Contractors, Take Note: Illinois Court Curtails Broad BIPA Exemption
Client Alert | 4 min read | 05.04.26
EPA Places Microplastics, PFAS, Pharmaceuticals, and DBPs on Draft Sixth Contaminant Candidate List
Client Alert | 4 min read | 04.27.26
Gaming Addiction Litigation: Turner v. Epic Games & Roblox and What It Means for the Industry
Client Alert | 2 min read | 04.24.26
Client Alert | 3 min read | 04.22.26
Counterfeiting Litigation Targets Online Marketplaces
Client Alert | 4 min read | 04.15.26
Client Alert | 4 min read | 04.08.26
Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA